ACADIA Pharmaceuticals (ACAD) shares have edged lower in pre-market trading after falling nearly 2% on Thursday. ACAD has been moving after reporting its earnings. The earnings were closely watched as the company began commercialization of its PDP drug Nuplazid. The drug was approved by the FDA in April this year. Net product sales were just $97,000 for the quarter. However, one must remember that during launch physicians have been able to prescribe patients a 30-day free trial of NUPLAZID upon initiation of therapy, for which no revenue is recognized.  The more important thing to watch is operating expenses and the company’s outlook on costs. SG&A expenses rose to $50.8 million in the second quarter. ACAD ended Q2 with more than $400 million in cash so the company has sufficient funds to meet the increasing expenses. The next catalyst for ACAD is top-line results from pimavanserin Phase 2 study in ADP.